Biogen's (BIIB) 3 New Trifectera Patents Could Signal Claims for Monetary Damages From Generic Tecfidera Companies - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $351.00 price target on Biogen (NASDAQ: BIIB) after the United ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
